PTPRD mutation is a prognostic biomarker for sensitivity to ICIs treatment in advanced non-small cell lung cancer-Reference-Cited by-同舟云学术

PTPRD mutation is a prognostic biomarker for sensitivity to ICIs treatment in advanced non-small cell lung cancer

Published:2023-08-18 Issue:16 Volume:15 Page:8204-8219
ISSN:1945-4589
Container-title:Aging
language:en
Short-container-title:Aging

Author:

Ren Zhixuan¹,Wang Li²,Leng Chaohui³

Affiliation:

1. Department of Radiation Oncology, Huadong Hospital, Fudan University, Shanghai 200433, P.R. China

2. Department of Medical Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai 200433, P.R. China

3. Department of Oncology, Jiujiang University Affilliated Hospital, Jiujiang 332000, P.R. China

Publisher

Impact Journals, LLC

Subject

Cell Biology,Aging

Reference44 articles.

1. Cancer treatment and survivorship statistics, 2019.;Siegel;CA Cancer J Clin,2019

2. The biology and management of non-small cell lung cancer.;Boshoff;Nature,2018

3. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.;Zhang;Lancet,2019

4. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.;Hotta;J Clin Oncol,2021

5. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.;Peled;J Clin Oncol,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of nomogram associated with durable clinical benefit gene for advanced non-small cell lung cancer with sensitivity to responsive to immunotherapy;Heliyon;2024-04